Nov 14, 2022 Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Nov 3, 2022 Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
Sep 16, 2022 Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Sep 13, 2022 Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
